Currently out of the existing stock ratings of David Friedman, 2 are a SELL (100%).

David Friedman

Work Performance Price Targets & Ratings Chart

Analyst David Friedman, carries an average stock price target met ratio of 100% that have a potential upside of 62.69% achieved within 356 days. Previously, David Friedman worked at MORGAN STANLEY.

David Friedman’s has documented 4 price targets and ratings displayed on 3 stocks.

Most recent stock forecast was given on INVA, Innoviva at 21-Jul-2014.

Wall Street Analyst David Friedman

Analyst best performing recommendations are on INVA (INNOVIVA).
The best stock recommendation documented was for INVA (INNOVIVA) at 2/7/2014. The price target of $13 was fulfilled within 276 days with a profit of $14.36 (52.49%) receiving and performance score of 1.9.

Average potential price target upside

THRX Theseus Pharmaceuticals INVA Innoviva ISEE IVERIC bio

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 02-Nov-2021

$7

$2.94 (72.41%)

3 years 2 months 29 days ago
(14-Jul-2023)

0/2 (0%)

$4.34 (163.16%)

Buy Since 10-Mar-2023

$23

3 years 2 months 29 days ago
(14-Jul-2023)

0/3 (0%)

$23 (0.00%)

Buy Since 30-Jun-2022

$9

$4.94 (121.67%)

$22

3 years 2 months 29 days ago
(14-Jul-2023)

0/3 (0%)

$9 (0.00%)

Buy Since 02-Nov-2021

$7

$2.94 (72.41%)

$24

3 years 2 months 29 days ago
(14-Jul-2023)

0/2 (0%)

$4.34 (163.16%)

Hold Since 23-May-2023

$24

3 years 4 months 20 days ago
(23-May-2023)

0/1 (0%)

$16.2 (207.69%)

Show more analysts

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?